in which Sanofi and Novo Nordisk have eclipsed Lilly, a pioneer in the field. The list price of Basaglar will be $316.85 for a pack of five pens, 15% below the list price of Lantus. The companies ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial form or as a disposable pen ... version of Sanofi’s Lantus (insulin glargine).

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...